The impact of obesity and metabolic syndrome on chronic hepatitis B and drug-induced liver disease

Clinics in Liver Disease

Volumn 18, Issue 1, 2014, Pages 165-178

  Pais, Raluca ^a   Rusu, Elena ^b   Ratziu, Vlad ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b FUNDENI CLINICAL INSTITUTE   (Romania)

Author keywords

Chronic hepatitis B; Cirrhosis; Drug induced liver injury; Fatty liver; Fibrosis; Hepatocellular carcinoma; Metabolic syndrome; Steatosis

Indexed keywords

ENFLURANE; HALOTHANE; ISOFLURANE; METHOTREXATE; PARACETAMOL;

CANCER RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; HALOTHANE LIVER INJURY; HEPATITIS B; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER INJURY; LIVER TOXICITY; METABOLIC SYNDROME X; OBESITY; OUTCOME ASSESSMENT; PREVALENCE; REVIEW; RISK ASSESSMENT; TOXIC HEPATITIS;

CHRONIC HEPATITIS B; CIRRHOSIS; DRUG-INDUCED LIVER INJURY; FATTY LIVER; FIBROSIS; HEPATOCELLULAR CARCINOMA; METABOLIC SYNDROME; STEATOSIS;

ACETAMINOPHEN; ANESTHETICS; ANIMALS; DRUG-INDUCED LIVER INJURY; FATTY LIVER; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; METHOTREXATE; OBESITY; PREVALENCE; RISK FACTORS; TRANS-ACTIVATORS;

EID: 84888054464     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2013.09.015     Document Type: Review

References (83)

1. Hart C.L., Morrison D.S., Batty G.D., et al. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ 2010, 340:c1240.
2. Liu B., Balkwill A., Reeves G., et al. Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study. BMJ 2010, 340:c912.
3. Younossi Z.M., McCullough A.J. Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver Int 2009, 29(Suppl 2):3-12.
4. Naveau S., Giraud V., Borotto E., et al. Excess weight is a risk factor for alcoholic liver disease. Hepatology 1997, 25:108-111.
5. Raynard B., Balian A., Fallik D., et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002, 35:635-638.
6. Bellentani S., Saccoccio G., Masutti F., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000, 132:112-117.
7. Fan J.G., Farrell G.C. Epidemiology of non-alcoholic fatty liver disease in China. JHepatol 2009, 50:204-210.
8. Papatheodoridis G.V., Chrysanthos N., Savvas S., et al. Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. JViral Hepat 2006, 13:303-310.
9. Altlparmak E., Koklu S., Yalinkilic M., et al. Viral and host causes of fatty liver in chronic hepatitis B. World J Gastroenterol 2005, 11:3056-3059.
10. Thomopoulos K.C., Arvaniti V., Tsamantas A.C., et al. Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. Eur J Gastroenterol Hepatol 2006, 18:233-237.
11. Tsochatzis E., Papatheodoridis G.V., Manesis E.K., et al. Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C. Dig Liver Dis 2007, 39:936-942.
12. Tsochatzis E., Papatheodoridis G.V., Manesis E.K., et al. Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2007, 27:80-89.
13. Minakari M., Molaei M., Shalmani H.M., et al. Liver steatosis in patients with chronic hepatitis B infection: host and viral risk factors. Eur J Gastroenterol Hepatol 2009, 21:512-516.
14. Petta S., Cammà C., Marco V.D., et al. Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. Liver Int 2011, 31:507-515.
15. Rozario R., Ramakrishna B. Histopathological study of chronic hepatitis B and C: a comparison of two scoring systems. JHepatol 2003, 38:223-229.
16. Gordon A., McLean C.A., Pedersen J.S., et al. Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis. JHepatol 2005, 43:38-44.
17. Peng D., Han Y., Ding H., et al. Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors. JGastroenterol Hepatol 2008, 23:1082-1088.
18. Shi J.P., Fan J.G., Wu R., et al. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. JGastroenterol Hepatol 2008, 23:1419-1425.
19. Yun J.W., Cho Y.K., Park J.H., et al. Hepatic steatosis and fibrosis in young men with treatment-naïve chronic hepatitis B. Liver Int 2009, 29:878-883.
20. Wong G.L., Wong V.W., Choi P.C., et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut 2009, 58:111-117.
21. Kumar M., Choudhury A., Manglik N., et al. Insulin resistance in chronic hepatitis B virus infection. Am J Gastroenterol 2009, 104:76-82.
22. Park S.H., Kim D.J., Lee H.Y. Insulin resistance is not associated with histologic severity in nondiabetic, noncirrhotic patients with chronic hepatitis B virus infection. Am J Gastroenterol 2009, 104:1135-1139.
23. Zheng R.D., Xu C.R., Jiang L., et al. Predictors of hepatic steatosis in HBeAg-negative chronic hepatitis B patients and their diagnostic values in hepatic fibrosis. Int J Med Sci 2010, 7:272-277.
24. Lesmana L.A., Lesmana C.R., Pakasi L.S., et al. Prevalence of hepatic steatosis in chronic hepatitis B patients and its association with disease severity. Acta Med Indones 2012, 44:35-39.
25. Machado M.V., Oliveira A.G., Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients- meta-analysis of risk factors and comparison with hepatitis C infected patients. JGastroenterol Hepatol 2011, 26:1361-1367.
26. Bondini S., Kallman J., Wheeler A., et al. Impact of non-alcoholic fatty liver disease on chronic hepatitis B. Liver Int 2007, 27:607-611.
27. Stepanova M., Rafiq N., Younossi Z.M. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut 2010, 59:1410-1415.
28. Wong V.W., Wong G.L., Chu W.C., et al. Hepatitis B virus infection and fatty liver in the general population. JHepatol 2012, 56:533-540.
29. Kim K.H., Shin H.J., Kim K., et al. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARγ. Gastroenterology 2007, 132:1955-1967.
30. Na T.Y., Shin Y.K., Roh K.J., et al. Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma. Hepatology 2009, 49:1122-1131.
31. Kim K., Kim Kook H., Kim Hyeong H., et al. Hepatitis B virus X protein induces lipogenic transcription factor SREBP1 and fatty acid synthase through the activation of nuclear receptor LXRα. Biochem J 2008, 416:219.
32. Bedossa P., Moucari R., Chelbi E., et al. Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study. Hepatology 2007, 46:380-387.
33. Wong V.W., Wong G.L., Yu J., et al. Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese. Am J Gastroenterol 2009, 105:132-138.
34. Zhang Z., Pan Q., Duan X.Y., et al. Fatty liver reduces hepatitis B virus replication in a genotype B hepatitis B virus transgenic mice model. JGastroenterol Hepatol 2012, 27:1858-1864.
35. Vigano M., Valenti L., Lampertico P., et al. Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B. Hepatology 2013, 58(4):1245-1252.
36. Yu M.W., Shih W.L., Lin C.L., et al. Body-mass index and progression of hepatitis B: a population-based cohort study in men. JClin Oncol 2008, 26:5576-5582.
37. Chao L.T., Wu C.F., Sung F.Y., et al. Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort. Carcinogenesis 2011, 32:876-881.
38. Chen Y., Wang X., Wang J., et al. Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. Eur J Cancer 2012, 48:2137-2145.
39. Welzel T.M., Graubard B.I., Zeuzem S., et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011, 54:463-471.
40. El-Serag H.B., Hampel H., Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006, 4:369-380.
41. Chen C.L., Yang H.I., Yang W.S., et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008, 135:111-121.
42. Wang C.S., Yao W.J., Chang T.T., et al. The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses. Cancer Epidemiol Biomarkers Prev 2009, 18:2054-2060.
43. Ateş F. Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B. World J Gastroenterol 2011, 17:4517.
44. Cindoruk M., Karakan T., Unal S. Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection. JClin Gastroenterol 2007, 41:513-517.
45. Jin X., Chen Y.P., Yang Y.D., et al. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PLoS One 2012, 7:e34198.
46. Marcellin P., Gane E., Buti M., et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013, 381:468-475.
47. Stuart B., Lloyd J., Zhao L., et al. Obesity, disease burden, and prescription spending by community-dwelling Medicare beneficiaries. Curr Med Res Opin 2008, 24:2377-2387.
48. Yang S.Q., Lin H.Z., Lane M.D., et al. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 1997, 94:2557-2562.
49. Yang S., Lin H., Diehl A.M. Fatty liver vulnerability to endotoxin-induced damage despite NF-kappaB induction and inhibited caspase 3 activation. Am J Physiol Gastrointest Liver Physiol 2001, 281:G382-G392.
50. Feldstein A.E., Canbay A., Guicciardi M.E., et al. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. JHepatol 2003, 39:978-983.
51. Feldstein A.E., Werneburg N.W., Canbay A., et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004, 40:185-194.
52. Reinartz A., Ehling J., Leue A., et al. Lipid-induced up-regulation of human acyl-CoA synthetase 5 promotes hepatocellular apoptosis. Biochim Biophys Acta 2010, 1801:1025-1035.
53. Soden J.S., Devereaux M.W., Haas J.E., et al. Subcutaneous vitamin E ameliorates liver injury in an invivo model of steatocholestasis. Hepatology 2007, 46:485-495.
54. Bjorkegren J., Beigneux A., Bergo M.O., et al. Blocking the secretion of hepatic very low density lipoproteins renders the liver more susceptible to toxin-induced injury. JBiol Chem 2002, 277:5476-5483.
55. Cortez-Pinto H., Chatham J., Chacko V.P., et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 1999, 282:1659-1664.
56. Chalasani N., Gorski J.C., Asghar M.S., et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 2003, 37:544-550.
57. Weltman M.D., Farrell G.C., Hall P., et al. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998, 27:128-133.
58. Niemela O., Parkkila S., Juvonen R.O., et al. Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases. JHepatol 2000, 33:893-901.
59. Aubert J., Begriche K., Knockaert L., et al. Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role. Clin Res Hepatol Gastroenterol 2011, 35:630-637.
60. Fromenty B. Drug-induced liver injury in obesity. JHepatol 2013, 58:824-826.
61. Chalasani N., Björnsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010, 138:2246-2259.
62. Navarro V.J., Senior J.R. Drug-related hepatotoxicity. NEngl J Med 2006, 354:731-739.
63. Sgro C. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002, 36:451-455.
64. Björnsson E.S., Bergmann O.M., Björnsson H.K., et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013, 144:1419-1425.e1-3.
65. Andrade R.J., Lucena M.I., Fernandez M.C., et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005, 129:512-521.
66. Tarantino G., Conca P., Basile V., et al. Aprospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res 2007, 37:410-415.
67. Chalasani N., Fontana R.J., Bonkovsky H.L., et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008, 135:1924-1934. 1934.e1-4.
68. Bjornsson E., Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005, 42:481-489.
69. El-Serag H.B., Everhart J.E. Diabetes increases the risk of acute hepatic failure. Gastroenterology 2002, 122:1822-1828.
70. Ostapowicz G., Fontana R.J., Schiodt F.V., et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002, 137:947-954.
71. Nguyen G.C., Sam J., Thuluvath P.J. Hepatitis C is a predictor of acute liver injury among hospitalizations for acetaminophen overdose in the United States: a nationwide analysis. Hepatology 2008, 48:1336-1341.
72. Begriche K., Massart J., Robin M.A., et al. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology 2013, 58(4):1497-1507.
73. Rosenberg P., Urwitz H., Johannesson A., et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. JHepatol 2007, 46:1111-1118.
74. Malatjalian D.A., Ross J.B., Williams C.N., et al. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol 1996, 10:369-375.
75. Laharie D., Seneschal J., Schaeverbeke T., et al. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study. JHepatol 2010, 53:1035-1040.
76. Laharie D., Zerbib F., Adhoute X., et al. Diagnosis of liver fibrosis by transient elastography (FibroScan) and non-invasive methods in Crohn's disease patients treated with methotrexate. Aliment Pharmacol Ther 2006, 23:1621-1628.
77. Dugan C.M., MacDonald A.E., Roth R.A., et al. Amouse model of severe halothane hepatitis based on human risk factors. JPharmacol Exp Ther 2010, 333:364-372.
78. Gunaratnam N.T., Benson J., Gandolfi A.J., et al. Suspected isoflurane hepatitis in an obese patient with a history of halothane hepatitis. Anesthesiology 1995, 83:1361-1364.
79. Christ D.D., Satoh H., Kenna J.G., et al. Potential metabolic basis for enflurane hepatitis and the apparent cross-sensitization between enflurane and halothane. Drug Metab Dispos 1988, 16:135-140.
80. Hasan F. Isoflurane hepatotoxicity in a patient with a previous history of halothane-induced hepatitis. Hepatogastroenterology 1998, 45:518-522.
81. Kusuma H.R., Venkataramana N.K., Rao S.A., et al. Fulminant hepatic failure after repeated exposure to isoflurane. Indian J Anaesth 2011, 55:290-292.
82. Turner G.B., O'Rourke D., Scott G.O., et al. Fatal hepatotoxicity after re-exposure to isoflurane: a case report and review of the literature. Eur J Gastroenterol Hepatol 2000, 12:955-959.
83. Persico M. Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: differences and similarities. World J Gastroenterol 2009, 15:462.